View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Comment
May 13, 2022

Smartphone app could screen for neurological disease at home

University of California researchers have developed an app that uses a near-infrared camera to check for neurological disease.

By GlobalData Healthcare

Abnormal appearance and functionality of a person’s pupils can be used to inform the diagnosis of neurological disease. The pupil can dilate, or shrink, to adjust the amount of light that enters the eye. However, the pupil is also connected to several complex neurological processes—this connection between pupillary response and neurological processes has been incorporated into the diagnostic process for diseases like Alzheimer’s disease (AD), Parkinson’s disease, schizophrenia, and attention deficit hyperactivity disorder (ADHD).

Physicians use pupillometers to measure a patient’s pupils. Unfortunately, clinical-grade pupillometers that work on a wide variety of eye colors are costly and are currently only found in clinical or laboratory settings. The limited access to these pupillometers slows down the diagnosis time for many neurological diseases. However, researchers at the University of California San Diego have developed a smartphone app that uses a near-infrared camera, which is built into newer smartphones for facial recognition, to measure a person’s pupil.

These measurements could then be used to assess a person’s pupil response time after stimulated, which could lead to a faster diagnosis of neurological diseases, like AD. As such, GlobalData epidemiologists expect that the diagnosed prevalent cases of AD, and other neurological disease, may increase over the next 10 years due to increased diagnosis attributed to at-home pupillometry tests.

A recent study published in CHI Conference on Human Factors in Computing Systems by Barry and colleagues, from the University of California San Diego, compared the novel smartphone pupillometer to the Neuroptics PLR 2000 pupillometer (which is normally used by physicians). Fifteen participants of different ethnicities and eye colors were recruited and asked to use both methods to measure their pupils. The results of the study found that the smartphone pupillometer was able to successfully measure pupil size, and there was no statistical difference in success between light and dark eye colors. Although successful, the measurements may not be as accurate as those taken in a clinical setting, where a person’s head is held still by a trained professional.

This inaccuracy at home may lead to a change in the center of the pupil between readings, which significantly changes the disparity and accuracy of the measurement. Additionally, Barry and colleagues observed issues with the useability of the app among elderly participants. As neurological diseases like Alzheimer’s and Parkinson’s disease are often diagnosed in older age, it is important that these types of technological barriers are overcome to ensure the measurements can be applied to general practice.

As smartphones become more advanced, there is hope that mobile pupillometry could become a widespread healthcare tool available to everyone. Across the eight major pharmaceutical markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and China), GlobalData epidemiologists forecast approximately 10,156,000 diagnosed prevalent cases of AD in 2022, which is expected to increase to 12,348,000 diagnosed prevalent cases by 2028. However, should this new diagnostic tool be adopted, diagnosed prevalent cases of AD will likely surpass current forecast estimates.

GlobalData epidemiologists also anticipate a further increase in diagnosed prevalent cases of other neurological diseases like Parkinson’s disease, ADHD, and schizophrenia in light of these technological advances. In future, further research is needed to better understand and elaborate on the findings from this study.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU